Longeveron

Longeveron is a company listed under the stock ticker LGVN (US).

View the org chart displaying its 15 main executives

Most searched biographies at Longeveron

• Wa'el Hashad, Chief Executive Officer and Director
• Rock Soffer, Director
• Ursula Ungaro, Director

Popular executive movements at Longeveron

• Cathy Ross, Director, has left the company  (posted on May 13 2024).
• Jeffrey Pfeffer, Director, has left the company  (posted on May 13 2024).
• Richard Kender has joined the company as Director  (posted on May 13 2024).

Create your alert
to follow the executive moves at Longeveron.

Longeveron has 2,288 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Attovia Therapeutics has just announced a $150 Million fundraising (posted on May 14 2024).
• Bruker has announced the acquisition of NanoString Technologies  (posted on May 13 2024).
• Aardvark Therapeutics has just announced a $85 Million fundraising (posted on May 12 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Carl Gordon - Director at Adicet Bio
• Vik Bajaj - Director at Interline Therapeutics

Learn more about the Biotechnology industry >

Press releases by Longeveron

• Longeveron Announces Board of Directors Planned Transitions
• Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
• Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
• Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
• Longeveron to Present at the Planet MicroCap Showcase
• Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
• Longeveron Announces Pricing of $5.25 Million Public Offering
• Longeveron Announces Closing of $5.2 Million Public Offering
• Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
• Longeveron Announces 1-for-10 Reverse Stock Split
• View more press releases Close

Social media about Longeveron

• Longeveron on Wikipedia, Google News & Yahoo Finance
• Longeveron on LinkedIn, Twitter & YouTube

Contact by email its executives including Wa'el Hashad

Call Longeveron at +1 305...

View the org chart

Register to receive your alert

Report an error